“ In 2018, we led Global Blood
Therapeutics’equityoffering,
helping the company to advance
the development of its lead
medicine for sickle cell.”
Michael Brock
Managing Director
Wells Fargo Securities“ Wells Fargo has belief in what we’re
doing – trying to change sickle cell
from a disease that kills you to
one you can live with. We hope to
make our fi rst medicine, voxelotor,
available to patients next year.”
Dr. Ted Love
CEO
Global Blood Therapeutics
Learn more about Wells Fargo’s Healthcare Banking
wellsfargo.com/healthcarebanking